Abstract
A 188-amino acid NH2-terminal fragment of recombinant human lipocortin-1 (rhLC-1) (LC-1 fragment) mimics glucocorticoid (and rhLC-1) inhibition of corticotrophin-releasing hormone (CRH)-stimulated release of adrenocorticotrophin (ACTH) from rat anterior pituitary and cytokine-stimulated CRH release from rat hypothalamus in vitro. The present in vivo study examined the effect of LC-1 fragment on CRH stimulation of rat plasma ACTH and release of rat hypothalamic CRH. Coinjection of LC-1 fragment inhibited the increase in plasma ACTH concentration stimulated by either central (76% inhibition) or peripheral (72% inhibition) injection of CRH and abolished the (62%) depletion of hypothalamic immunoreactive (ir)CRH stimulated by central injection of interleukin-1 beta. Central injection of the CRH functional analogue sauvagine led to a 46% reduction (P > 0.05, 2-way analysis of variance) in rat hypothalamic irCRH content, which was reversed by coinjection of LC-1 fragment. These results indicate that LC-1 can suppress the activity of the hypothalamic-pituitary axis in the rat, possibly by inhibiting a positive feedback mechanism controlling release of hypothalamic CRH.
Original language | English |
---|---|
Journal | Am J Physiol |
Volume | 270( 1 Pt 2) |
Publication status | Published - Jan 1996 |
Keywords
- Animals
- pharmacology: Annexin I
- blood: Corticotropin
- antagonists & inhibitors: Corticotropin-Releasing Hormone
- Human
- metabolism: Hypothalamus
- Immunoradiometric Assay
- pharmacology: Interleukin-1
- Male
- Osmolar Concentration
- pharmacology: Peptide Fragments
- pharmacology: Peptides
- Radioimmunoassay
- Rats
- Rats, Sprague-Dawley
- Recombinant Proteins
- Support, Non-U.S. Gov't